The ongoing pandemic caused by mpox virus (MPXV) has become an international public
health emergency that poses a significant threat to global health. The vaccinia virus Tiantan …

When the Mpox virus (MPXV) began spreading globally in 2022, it became critical to
evaluate whether residual immunity from smallpox vaccination provided cross-protection. To …

Mpox virus (MPXV) caused a multi-country outbreak in non-endemic areas in 2022.
Following historic success of smallpox vaccination with vaccinia virus (VACV)-based …

Abstract Information on the immune response during the mpox virus (MPXV) infection is still
scarce or limited to past studies when cross‐reactive immunity from smallpox vaccination …

Since May 2022, human mpox cases have increased unexpectedly in non-endemic
countries. The first imported case of human mpox in Hong Kong was reported in September …

Background Vaccination against mpox (formerly known as monkeypox), an infectious
disease caused by the monkeypox virus (MPXV), is needed to prevent outbreaks and …

Smallpox vaccination may confer cross-protection to mpox. We evaluated vaccinia virus
antibodies in 162 persons≥ 50 years of age in Spain; 68.5% had detectable antibodies …

Mpox (monkeypox) infection cases increased recently in non-Mpox outbreak areas,
potentially causing an international threat. The desire to defend against a potential outbreak …

The Mpox virus (MPXV) is endemic in certain countries in Central and West Africa, where
several mammalian species, especially rodents, are natural reservoirs. However, the MPXV …

In early 2022, a cluster of Monkeypox (now termed MPOX) virus (MPXV) cases were
identified within the UK with no prior travel history to MPXV-endemic regions, suggesting …